O estado da arte do tratamento da doença de Huntington / The state of the art on treatment of Huntington's disease
DOI:
https://doi.org/10.34119/bjhrv4n3-337Keywords:
Doença de Huntington, Tratamento.Abstract
A doença de Huntington é uma patologia neurodegenerativa, progressiva, autossômica dominante, poliglutamínica e de determinação genética, caracterizada clinicamente por distúrbio motor, declínio cognitivo e transtornos psiquiátricos que gera grande impacto na saúde e qualidade de vida dos pacientes e de seus familiares. Apesar de ser uma doença rara e sem tratamentos que comprovadamente são modificadores do curso da doença, muitas alternativas terapêuticas têm surgido nos últimos anos. O presente estudo trata-se de uma revisão de literatura acerca das mais modernas e promissoras possibilidades de tratamento medicamentoso, não medicamentoso e ainda outras formas de intervenção para essa patologia.
References
Bartlett, D. M., Dominguez D, J. F., Lazar, A. S., Kordsachia, C. C., Rankin, T. J., Lo, J., Govus, A. D., Power, B. D., Lampit, A., Eastwood, P. R., Ziman, M. R., & Cruickshank, T. M. (2020). Multidisciplinary rehabilitation reduces hypothalamic grey matter volume loss in individuals with preclinical Huntington’s disease: A nine-month pilot study. Journal of the Neurological Sciences, 408(August 2019), 116522. https://doi.org/10.1016/j.jns.2019.116522
Bruzelius, E., Scarpa, J., Zhao, Y., Basu, S., Faghmous, J. H., & Baum, A. (2019). Huntington’s disease in the United States: Variation by demographic and socioeconomic factors. Movement Disorders, 34(6), 858–865. https://doi.org/10.1002/mds.27653
Burnip, E., Wallace, E., Gozdzikowska, K., & Huckabee, M. L. (2020). A Systematic Review of Rehabilitation for Corticobulbar Symptoms in Adults with Huntington’s Disease. Journal of Huntington’s Disease, 9(1), 1–12. https://doi.org/10.3233/JHD-190384
Caron, N. S., Wright, G. E. B., Hayden, M. R., & Frcp, C. (2019). Huntington Disease Summary Suggestive Findings. 1–34.
Colpo, G. D., Furr Stimming, E., & Teixeira, A. L. (2019). Stem cells in animal models of Huntington disease: A systematic review. Molecular and Cellular Neuroscience, 95(January), 43–50. https://doi.org/10.1016/j.mcn.2019.01.006
Cruickshank, T. M., Reyes, A. P., Penailillo, L. E., Pulverenti, T., Bartlett, D. M., Zaenker, P., Blazevich, A. J., Newton, R. U., Thompson, J. A., Lo, J., & Ziman, M. R. (2018). Effects of multidisciplinary therapy on physical function in Huntington’s disease. Acta Neurologica Scandinavica, 138(6), 500–507. https://doi.org/10.1111/ane.13002
Eddy, C. M., Shapiro, K., Clouter, A., Hansen, P. C., & Rickards, H. E. (2017). Transcranial direct current stimulation can enhance working memory in Huntington’s disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 77, 75–82. https://doi.org/10.1016/j.pnpbp.2017.04.002
Elgart, A., Zur, A. A., Mimrod, D., Dror, V., Bar-Ilan, O., Korver, T., & Spiegelstein, O. (2019). The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women. European Journal of Clinical Pharmacology, 75(1), 41–49. https://doi.org/10.1007/s00228-018-2549-7
Frank, S., Testa, C. M., Stamler, D., Kayson, E., Davis, C., Edmondson, M. C., Kinel, S., Leavitt, B., Oakes, D., O’Neill, C., Vaughan, C., Goldstein, J., Herzog, M., Snively, V., Whaley, J., Wong, C., Suter, G., Jankovic, J., Jimenez-Shahed, J., … Christopher, E. (2016). Effect of deutetrabenazine on chorea among patients with huntington disease?: A randomized clinical trial. JAMA - Journal of the American Medical Association, 316(1), 40–50. https://doi.org/10.1001/jama.2016.8655
Gelderblom, H., Wüstenberg, T., McLean, T., Mütze, L., Fischer, W., Saft, C., Hoffmann, R., Süssmuth, S., Schlattmann, P., Van Duijn, E., Landwehrmeyer, B., & Priller, J. (2017). Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebocontrolled, prospective crossover trial. PLoS ONE, 12(3), 1–17. https://doi.org/10.1371/journal.pone.0173872
Gil-mohapel, J. M., & Rego, A. C. (2011). Doença de Huntington?: Uma Revisão dos Aspectos Fisiopatológicos. 19(4), 724–734.
Kempnich, C. L., Wong, D., Georgiou-Karistianis, N., & Stout, J. C. (2017). Feasibility and Efficacy of Brief Computerized Training to Improve Emotion Recognition in Premanifest and Early-Symptomatic Huntington’s Disease. Journal of the International Neuropsychological Society, 23(4), 314–321. https://doi.org/10.1017/S1355617717000145
Labuschagne, I., Poudel, G., Kordsachia, C., Wu, Q., Thomson, H., Georgiou-Karistianis, N., & Stout, J. C. (2018). Oxytocin selectively modulates brain processing of disgust in Huntington’s disease gene carriers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 81(September 2017), 11–16. https://doi.org/10.1016/j.pnpbp.2017.09.023
López-Sendón Moreno, J. L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M. A. A., García de Yébenes, M. J., Tolón, R. M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., García-Bermejo, M. L., Fernández Ruiz, J., Guzmán, M., & García de Yébenes Prous, J. (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. Journal of Neurology, 263(7), 1390–1400. https://doi.org/10.1007/s00415-016-8145-9
Martelli, A. (2014). Aspectos clínicos e fisiopatológicos da Doença de Huntington. Arch Health Invest, 3, 32–39.
McGarry, A., Auinger, P., Kieburtz, K., Geva, M., Mehra, M., Abler, V., Grachev, I. D., Gordon, M. F., Savola, J. M., Gandhi, S., Papapetropoulos, S., & Hayden, M. (2020). Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. Journal of Huntington’s Disease, 9(2), 173–184. https://doi.org/10.3233/JHD-190393
McGarry, A., Kieburtz, K., Abler, V., Grachev, I. D., Gandhi, S., Auinger, P., Papapetropoulos, S., & Hayden, M. (2017). Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s Disease. Journal of Huntington’s Disease, 6(3), 189–199. https://doi.org/10.3233/JHD-170241
Mcgarry, A., Mcdermott, M., Kieburtz, K., Blieck, E. A. De, Beal, F., Shoulson, I., Gilbert, P., Mallonee, W. M., Guttman, M., Wojcieszek, J., Ledoux, M. S., Jenkins, M., Rosas, H. D., Nance, M., Biglan, K., Dubinsky, R. M., Chou, K., Walker, F., Martin, W., … Rodriguez, R. (2016). placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology, 88, 152–159.
Mirek, E., Filip, M., Chwa?a, W., Szymura, J., Pasiut, S., Banaszkiewicz, K., Bar, M. R., & Szczudlik, A. (2018). The influence of motor ability rehabilitation on temporal-spatial parameters of gait in Huntington’s disease patients on the basis of a three-dimensional motion analysis system: An experimental trial. Neurologia i Neurochirurgia Polska, 52(5), 575–580. https://doi.org/10.1016/j.pjnns.2018.02.001
Morsy, S., Khalil, S. M., Doheim, M. F., Kamel, M. G., El-Basiony, D. S. M., Hassan, H. I. A., Eisa, A. A., Ngoc, C. T. A., Dang, N. P., Hirayama, K., Huy, N. T. (2019). Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis, Acta Neuropsychiatrica, 31 (4), 175-185. https://doi.org/10.1017/neu.2019.11
Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., & Jette, N. (2012). The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Movement Disorders, 27(9), 1083–1091. https://doi.org/10.1002/mds.25075
Quinn, L., Hamana, K., Kelson, M., Dawes, H., Collett, J., Townson, J., Roos, R., van der Plas, A. A., Reilmann, R., Frich, J. C., Rickards, H., Rosser, A., & Busse, M. (2016). A randomized, controlled trial of a multi-modal exercise intervention in Huntington’s disease. Parkinsonism and Related Disorders, 31, 46–52. https://doi.org/10.1016/j.parkreldis.2016.06.023
Quinn, L., Kegelmeyer, D., Kloos, A., Rao, A. K., Busse, M., & Fritz, N. E. (2020). Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology, 94(5), 217–228. https://doi.org/10.1212/WNL.0000000000008887
Sadeghi, M., Barlow-Krelina, E., Gibbons, C., Shaikh, K. T., Fung, W. L. A., Meschino, W. S., & Till, C. (2017). Feasibility of computerized working memory training in individuals with Huntington disease. PLoS ONE, 12(4), 1–13. https://doi.org/10.1371/journal.pone.0176429
Schwartz, A. E., Van Walsem, M. R., Brean, A., & Frich, J. C. (2019). Therapeutic Use of Music, Dance, and Rhythmic Auditory Cueing for Patients with Huntington’s Disease: A Systematic Review. Journal of Huntington’s Disease, 8(4), 393–420. https://doi.org/10.3233/JHD-190370
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., Rosser, A., Kordasiewicz, H. B., Czech, C., Swayze, E. E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S. A., Paz, E., … Lane, R. M. (2019). Targeting Huntingtin Expression in Patients with Huntington’s Disease. New England Journal of Medicine, 380(24), 2307–2316. https://doi.org/10.1056/nejmoa1900907
Van Bruggen-Rufi, M. C. H., Vink, A. C., Wolterbeek, R., Achterberg, W. P., & Roos, R. A. C. (2017). The Effect of Music Therapy in Patients with Huntington’s Disease: A Randomized Controlled Trial. Journal of Huntington’s Disease, 6(1), 63–72. https://doi.org/10.3233/JHD-160229
Verny, C., Bachoud-Lévi, A. C., Durr, A., Goizet, C., Azulay, J. P., Simonin, C., Tranchant, C., Calvas, F., Krystkowiak, P., Charles, P., Youssov, K., Scherer, C., Prundean, A., Olivier, A., Reynier, P., Saudou, F., Maison, P., Allain, P., von Studnitz, E., & Bonneau, D. (2017). A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington’s disease. Movement Disorders, 32(6), 932–936. https://doi.org/10.1002/mds.27010
Yin, Z., Bai, Y., Zhang, H., Liu, H., Hu, W., Meng, F., Yang, A., & Zhang, J. (2020). An individual patient analysis of the efficacy of using GPi-DBS to treat Huntington’s disease. In Brain Stimulation (Vol. 13, Issue 6). Elsevier Inc. https://doi.org/10.1016/j.brs.2020.09.025
